Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals

Anti-Coagulants - Niger

Niger
  • The Anti-Coagulants market in Niger is anticipated to witness a substantial growth in revenue, with projections indicating a staggering figure of US$3.21m by the year 2024.
  • Moreover, this market is expected to display an annual growth rate (CAGR 2024-2029) of 8.72%, leading to a significant market volume of US$4.87m by 2029.
  • In terms of global comparison, United States is forecasted to generate the highest revenue in the Anti-Coagulants market, amounting to a remarkable US$16.74bn in 2024.
  • Niger is experiencing a growing demand for anti-coagulants due to an increase in cases of cardiovascular diseases.

Definition:
The Anti-Coagulants market covers drugs that prevent blood from clotting, i.e., that prolong the clotting time. Anti-coagulants are certain types of antithrombotics, which are often also called blood thinners. Neither thrombolytic drugs, which dissolve clots after they have formed, nor other anti-thrombotics, such as antiplatetelet drugs, are covered in this market.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Bristol Myers Squibb, Bayer, Sanofi, Johnson & Johnson

In-Scope

  • Blood clotting inhibitors

Out-Of-Scope

  • Anti-fibrinolytics
  • Anti-hypertensives
  • Other hematology drugs
  • Other anti-thrombotic agents, such as platelet aggregation inhibitors
  • Thrombolytic drugs
Anti-Coagulants: market data & analysis - Cover

Market Insights report

Anti-Coagulants: market data & analysis

Study Details

    Revenue

    Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.

    Most recent update: Mar 2024

    Analyst Opinion

    The Anti-Coagulants market in Niger is experiencing a steady growth in recent years.

    Customer preferences:
    Patients in Niger are increasingly opting for Anti-Coagulants due to the rise in cardiovascular diseases and stroke cases. The preference for Anti-Coagulants is also driven by the convenience of oral administration compared to traditional injectable methods.

    Trends in the market:
    The Anti-Coagulants market in Niger is being driven by the increasing awareness of the benefits of Anti-Coagulants in reducing the risk of stroke and other cardiovascular diseases. There is also a growing trend towards the use of novel oral anticoagulants (NOACs) as they offer better efficacy and safety profiles compared to traditional anticoagulants. The market is expected to continue to grow in the coming years due to the increasing prevalence of cardiovascular diseases in the country.

    Local special circumstances:
    Niger is a low-income country with a high burden of disease. The healthcare system in the country is underdeveloped, and access to healthcare services is limited, particularly in rural areas. The cost of Anti-Coagulants is relatively high, and this has limited access to these drugs for many patients. However, the government has taken steps to improve access to healthcare services, and this is expected to drive the growth of the Anti-Coagulants market in the country.

    Underlying macroeconomic factors:
    The economy of Niger is heavily dependent on agriculture, and the country is vulnerable to external shocks such as droughts and fluctuations in commodity prices. The healthcare sector in the country is underfunded, and this has limited the availability of healthcare services, including Anti-Coagulants. However, the government has made efforts to improve the healthcare sector, and this is expected to drive the growth of the Anti-Coagulants market in the country.

    Global Comparison

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Anti-Coagulants: market data & analysis - BackgroundAnti-Coagulants: market data & analysis - Cover

    Key Market Indicators

    Notes: Based on data from IMF, World Bank, UN and Eurostat

    Most recent update: Sep 2024

    Source: Statista Market Insights

    Explore more high-quality data on related topic

    Global pharmaceutical industry - statistics & facts

    The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.
    More data on the topic

    Contact

    Get in touch with us. We are happy to help.